Biomarker-based screening is revolutionizing cancer detection. The Cancer biomarker Market enables identification of tumors at earlier stages, improving treatment outcomes and survival rates.

Techniques like liquid biopsy and genetic sequencing are reducing dependency on invasive procedures. As screening becomes more accessible, the role of biomarkers in preventive oncology is growing stronger.

Market Outlook: The cancer biomarker market was valued at USD 15.9 billion in 2022 and is forecast to hit USD 27.8 billion by 2030, with a steady 9.8% CAGR.